EU Regulators Urged To Address Impact Of Decentralized Trials On Data Quality & Integrity

 
• By Vibha Sharma

The pharmaceutical industry has identified a range of statistical considerations relating to decentralized clinical trials that they want EU regulators to address to ensure data generated from such studies are acceptable for regulatory filings.

Healthcare business graph data and growth, Insurance Healthcare. Doctor analyzing medical of business report and medical examination with network connection on laptop screen.
Pharma needs assurance on the acceptability of data from decentralized clinical trials • Source: Shutterstock

More from Europe

More from Geography